Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee

Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical
Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)

Preliminary Analysis Shows Patient Cartilage Regrowth Within 3 Months

PALO ALTO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine
Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa
clinical trial for human adipose-derived mesenchymal precursor cell (haMPC)
therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of
intra-articular injections of autologous haMPCs in order to reduce
inflammation and repair damaged joint cartilage. Completed in Q4 2013, the
data shows no serious adverse events (SAE), suggesting ReJoin^TM cell therapy
for KOA patients is safe.

Three-month follow up data reveals statistically significant improvement in
KOA from the baseline in clinical scores for WOMAC, NRS-11, SF-36, and KSCRS
knee osteoarthritis indices, showing significantly reduced knee pain, improved
knee mobility, and prolonged walking distance. Reduction of bone marrow
lesions was observed in some patients. MRI examination revealed an increase in
cartilage thickness as early as three months after the therapy.

Data of three patients who have completed six-month follow-up has confirmed
the three-month findings, and full analysis of the six-month follow-up for all
patients in the trial is still ongoing. Additional studies are being carried
out to confirm the cartilage regrowth.

Presenting these results at the New York Stem Cell Summit on February 18,
2014, Wei (William) Cao, PhD, BM, Chief Executive Officer of Cellular
Biomedicine Group, Inc. said, "We are very excited with the preliminary
analysis of the trial. As far as we know this may be the first evidence that
adipose derived stem cells can regenerate human cartilage in three months. Our
preliminary conclusion from the three-month follow-up of the Phase I/IIa
clinical trial is that ReJoin^TM therapy is both safe and effective. We are
expecting the on-going Phase IIb study will provide more data to show the
advantages of ReJoin^TM cell therapy for KOA."

The SEC Edgar filing of Dr. Cao's presentation can be found online at

Knee Osteoarthritis in China

There are approximately 57 million people in China suffering from knee
osteoarthritis. As drug-based methods of management are ineffective, life
quality of KOA patients is compromised, and many patients with this disease
will degenerate to the point of requiring invasive artificial joint
replacement surgery.

About the Clinical Trial

Cellular Biomedicine Group's Phase I/IIa clinical trial studies the safety and
efficacy of CBMG's proprietary adipose-derived mesenchymal precursor cell
(haMPC)-based therapy for knee osteoarthritis. The trial is conducted by
Shanghai's Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao
Tong University School of Medicine.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental
stem cell, progenitor cell, and immune cell projects are the result of
research and development by scientists and doctors fromChinaandthe United
States. Our flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to U.S.
standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         Christopher Chu
         Director Investor Relations, Grayling
         +1 646 284-9426

Cellular Biomedicine Group Inc. Logo
Press spacebar to pause and continue. Press esc to stop.